Biocodex Unveils Promising Research at AES 2025 Annual Meeting in Atlanta Biocodex announces the presentation of 12 pivotal studies on Dravet syndrome treatment at AES 2025. Join us to learn more!

Biocodex Unveils Promising Research at AES 2025 Annual Meeting in Atlanta #United_States #Atlanta #Biocodex #Stiripentol #Dravet_Syndrome

UCB Unveils Key Research Advances at International Epilepsy Congress 2025 UCB showcases 26 scientific abstracts at the International Epilepsy Congress, emphasizing innovations in understanding and treating epilepsy disorders.

UCB Unveils Key Research Advances at International Epilepsy Congress 2025 #UCB #Epilepsy_Research #Brussels #Belgium #Dravet_Syndrome

New Study Confirms Long-Term Safety and Efficacy of FINTEPLA for Dravet Syndrome The final analysis of a long-term study reveals that FINTEPLA offers significant safety and effectiveness in reducing seizures in Dravet syndrome patients.

New Study Confirms Long-Term Safety and Efficacy of FINTEPLA for Dravet Syndrome #United_States #Atlanta #UCB #Dravet_Syndrome #FINTEPLA

Biocodex Unveils Groundbreaking Research on Dravet Syndrome at AES 2024 Annual Meeting Biocodex will showcase significant studies on Stiripentol, enhancing treatment strategies for Dravet syndrome at the AES 2024 Annual Meeting in Los Angeles.

Biocodex Unveils Groundbreaking Research on Dravet Syndrome at AES 2024 Annual Meeting #United_States #Los_Angeles #Biocodex #Stiripentol #Dravet_Syndrome